Below are citations directly from the Manufacturer's Package Inserts for Hepatitis-A (Merck & Glaxo Smithkline), MMR, Varicella (Chickenpox) Shingles and Pentacel Vaccines.
VAQTA [Hepatitis A Vaccine, Inactivated] is an inactivated whole virus vaccine derived from hepatitis A virus (HAV) grown in cell culture in human MRC-5 diploid fibroblasts. It contains inactivated virus of a strain which was originally derived by further serial passage of a proven attenuated strain. The virus is grown, harvested, purified by a combination of physical and high performance liquid chromatographic techniques developed at the Merck Research Laboratories, formalin inactivated, and then adsorbed onto aluminum hydroxide. One milliliter of the vaccine contains approximately 50 units (U) of hepatitis A virus antigen, which is purified and formulated without a preservative. Within the limits of current assay variability, the 5OU dose of VAQTA contains less than 0.1 mcg of non-viral protein, less than 4 x 10 mcg of DNA, less than 10 rncg of bovine albumin, and less than 0.8 mcg of formaldehyde. Other process chemical residuals are less than 10 parts per billion (ppb).
INFORMATION (PACKAGE INSERT)
(Hepatitis A Vaccine, Inactivated) is a noninfectious hepatitis A vaccine
developed and manufactured by SmithKline Beecham Biologicals. The virus (strain
HM175) is propagated in MRC5
cells. After removal of the cell culture medium, the cells are lysed to form a
suspension. This suspension is purified through ultrafiltration and gel
permeation chromatography procedures. Treatment of this lysate with formalin
ensures viral inactivation.
sterile suspension of inactivated virus; viral antigen activity is referenced to
a standard using an enzyme linked immunosorbent assay (ELISA), and is therefore
expressed in terms of ELISA Units (EL.U.).
as a sterile suspension for intramuscular administration. The vaccine is ready
for use without reconstitution; it must be shaken before administration to
assure a uniform suspension. After shaking, the vaccine is a homogeneous white
turbid suspension. Each 1 mL adult dose of vaccine consists of not less than
1440 EL.U. of viral antigen, adsorbed on 0.5 mg of aluminum, as aluminum
hydroxide. There are two pediatric dose formulations, each with its own dosing
schedule (see DOSAGE AND ADMINISTRATION).
formulations are: not less than 360 EL.U. of viral antigen/0.5 mL; not less than
720 EL.U. of viral antigen/0.5 mL. Each dose is adsorbed onto 0.25 mg of
aluminum, as aluminum hydroxide.
vaccine preparations also contain 0.5% (w/v) of 2-phenoxyethanol as a
preservative. Other excipients are: amino acid supplement (0.3% w/v) in a
phosphate-buffered saline solution and polysorbate 20 (0.05 mg/mL). Residual MRC5 cellular proteins (not more than 5 mcg/adult dose) and traces of formalin
(not more than 0.1 mg/mL) are present.
M-M-R II (Measles, Mumps, and Rubella Virus Vaccine Live) is a live virus vaccine for vaccination against measles (rubeola), mumps and rubella (German measles). M-M-R II is a sterile lyophilized preparation of (1) ATTENUVAX' (Measles Virus Vaccine Live), a more attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture; (2) MUMPSVAX* (Mumps Virus Vaccine Live), the Jerl Lynn (B level) strain of mumps virus propagated in chick embryo cell culture; and (3) MERUVAX'll (Rubella Virus Vaccine Live), the Wistar RA 27/3 strain of live attenuated rubella virus propagated in WI-38 human diploid lung fibroblasts.
The growth medium for measles and mumps is Medium 199 (a buffered salt solution containing vitamins and amino acids and supplemented with fetal bovine serum) containing SPGA (sucrose, phosphate, glutamate, and human albumin) as stabilizer and neomycin.
The growth medium for rubella is Minimum Essential Medium (MEM) [a buffered salt solution containing vitamins and amino acids and supplemented with fetal bovine serum] containing human serum albumin and neornycin. Sorbitol and hydrolyzed gelatin stabilizer are added to the individual virus harvests.
The cells, virus pools, fetal bovine serum, and human albumin are all screened for the absence of adventitious agents. Human albumin is processed using the Cohn cold ethanol fractionation procedure.
The reconstituted vaccine is for subcutaneous administration. Each 0.5 mL dose contains not less than 1,000 TCID(tissue culture infectious doses) of measles virus; 20,000 TCID of mumps virus; and 1,000 TCID of rubella virus. Each dose of the vaccine is calculated to contain sorbitol (14.5 mg), sodium phosphate, sucrose (1.9 mg), sodium chloride, hydrolyzed gelatin (14.5 mg), human albumin (0.3 mg), fetal bovine serum (<l ppm), other buffer and media ingredients and approximately 25 mcg of neomycin. The product contains no preservative.
[Varicella Virus Vaccine Live (Oka/Merck)]
VARIVAX [Varicella Virus Vaccine Live (Oka/Merck)] is a preparation of the Oka/Merck strain of live, attenuated varicella virus. The virus was initially obtained from a child with natural varicella, then introduced into human embryonic lung cell cultures, adapted to and propagated in embryonic guinea pig cell cultures and finally propagated in human diploid cell cultures (WI-38). Further passage of the virus for varicella vaccine was performed at Merck Research Laboratories (MRL) in human diploid cell cultures (MRC-5) that were free of adventitious agents. This live, attenuated varicella vaccine is a lyophilized preparation containing sucrose, phosphate, glutamate, and processed gelatin as stabilizers.
VARIVAX, when reconstituted as directed, is a sterile preparation for subcutaneous administration. Each 0.5 mL dose contains the following: a minimum of 1350 PFU (plaque forming units) of Oka/Merck varicella virus when reconstituted and stored at room temperature for 30 minutes, approximately 25 mg of sucrose, 12.5 mg hydrolyzed gelatin, 3.2 mg sodium chloride, 0.5 mg monosodium L-glutamate, 0.45 mg of sodium phosphate dibasic, 0.08 mg of potassium phosphate monobasic, 0.08 mg of potassium chloride; residual components of MRC-5 cells including DNA and protein; and trace quantities of sodium phosphate monobasic, EDTA, neomycin, and fetal bovine serum. The product contains no preservative.
ZOSTAVAX is a lyophilized preparation of the Oka/Merck strain of live, attenuated varicella-zoster virus (VZV). ZOSTAVAX, when reconstituted as directed, is a suspension for subcutaneous administration. Each 0.65-mL dose contains a minimum of 19,400 PFU (plaque-forming units) of Oka/Merck strain of VZV when reconstituted and stored at room temperature for up to 30 minutes.
Each dose contains 31.16 mg of sucrose, 15.58 mg of hydrolyzed porcine gelatin, 3.99 mg of sodium chloride, 0.62 mg of monosodium L-glutamate, 0.57 mg of sodium phosphate dibasic, 0.10 mg of potassium phosphate monobasic, 0.10 mg of potassium chloride; residual components of MRC-5 cells including DNA and protein; and trace quantities of neomycin and bovine calf serum. The product contains no preservatives.
Poliovirus Type 1, Type 2 and Type 3 are each grown in separate cultures of MRC-5 cells, a line of normal human diploid cells, by the microcarrier method.
(Found under "Description" Section 11 - page 18)
Send mail to
questions or comments about this web site.